Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography

Michel Meignan; Martin Hutchings; Lawrence H Schwartz

doi:10.1634/theoncologist.2015-0036

Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography

Oncologist. 2015 Aug;20(8):890-5. doi: 10.1634/theoncologist.2015-0036. Epub 2015 Jul 14.

Authors

Michel Meignan¹, Martin Hutchings², Lawrence H Schwartz²

Affiliations

¹ Centre Universitaire Hospitalier Henri Mondor, Lymphoma Study Association Imaging, Créteil, France; Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Columbia University Medical Center, New York, New York, USA michel.meignan@hmn.aphp.fr.
² Centre Universitaire Hospitalier Henri Mondor, Lymphoma Study Association Imaging, Créteil, France; Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Columbia University Medical Center, New York, New York, USA.

Abstract

This review focuses on the impact of new imaging guidelines for fluorodeoxyglucose-positron emission tomography (FDG-PET) on clinical practice and the future directions of lymphoma imaging.

Publication types

Review

MeSH terms

Fluorodeoxyglucose F18 / metabolism*
Humans
Lymphoma / diagnostic imaging*
Positron-Emission Tomography / methods*
Radiography

Substances

Fluorodeoxyglucose F18